Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing

Frontiers in Endocrinology

Endocrinology

Romana Netea-Maier¹  Petronella Ottevanger²  Peep Stalmeier³  Anna Koot⁴  Rosella Hermens⁵ 

[1] Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, Netherlands;Department of Internal Medicine, Division of Oncology, Radboud University Medical Center, Nijmegen, Netherlands;Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands;Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands;Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, Netherlands;Radboud Institute for Health Sciences, Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboud University Medical Center, Nijmegen, Netherlands;

关键词: thyroid cancer;    shared decision making;    surgery;    tyrosine kinase inhibitor;    decision aid;   

DOI  :  10.3389/fendo.2023.1162537

 received in 2023-02-09, accepted in 2023-05-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundPatient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with low-risk DTC and (2) the decision to start or delay starting the treatment with tyrosine kinase inhibitors (TKIs) in patients with advanced tumors.Material and methodsPtDAs for these two decisions were developed using the International Patient Decision Aids Standards (IPDAS) quality criteria in an iterative process of prototype development via alpha and beta testing by patients and physicians. The information content of the PtDAs was based on the available literature, current guidelines, and patient’s needs, preferences, and values.ResultsThe web-based PtDAs underwent two rounds of alpha testing, revisions, and beta testing. The PtDAs have the same structure, consisting of six steps: a general introduction, information about the treatment options, comparing the treatment options, knowledge questions, a values clarification exercise, and saving the information. The alpha testing (n = 8 patients, n = 10 physicians) showed that the PtDAs were highly acceptable and usable for decision-making. Results of the beta testing in 20 patients showed that two patients did not use the PtDA; the other 18 patients found that the PtDAs were readable (n = 17) and helpful (n = 14) for decision-making. All patients recommend using the PtDAs.ConclusionsEvidence-based PtDAs were created for patients with DTC for two different treatment decisions. Our final version was judged to be clear, balanced, and helpful in decision-making.

【 授权许可】

Unknown   
Copyright © 2023 Koot, Hermens, Ottevanger, Netea-Maier, Stalmeier and the COMBO study group